AMINOSYN-PF 7% Drug Patent Profile

Which patents cover Aminosyn-pf 7%, and what generic alternatives are available?

Aminosyn-pf 7% is a drug marketed by Otsuka Icu Medcl and is included in one NDA.

The generic ingredient in AMINOSYN-PF 7% is amino acids. There are three hundred and fifty drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the amino acids profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aminosyn-pf 7%

A generic version of AMINOSYN-PF 7% was approved as amino acids by B BRAUN on April 13^th, 2012.

Summary for AMINOSYN-PF 7%

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	AMINOSYN-PF 7% at DailyMed

Pharmacology for AMINOSYN-PF 7%

Drug Class

Amino Acid

US Patents and Regulatory Information for AMINOSYN-PF 7%

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka Icu Medcl	AMINOSYN-PF 7%	amino acids	INJECTABLE;INJECTION	019398-001	Sep 6, 1985		RX	No	No

AMINOSYN-PF 7%: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

AMINOSYN-PF 7%, a parenteral amino acid solution, holds a critical position in nutritional support for critically ill patients. Its market is driven by the prevalence of conditions necessitating intravenous nutrition and the increasing demand for specialized formulations. The financial trajectory is influenced by patent exclusivity, generic competition, manufacturing costs, and market penetration strategies.

What is AMINOSYN-PF 7%?

AMINOSYN-PF 7% is a sterile, nonpyrogenic intravenous solution. It contains amino acids, which are the building blocks of protein, intended for administration to patients requiring nutritional support when oral or enteral intake is not feasible or sufficient. The "PF" designation signifies "pediatric formulation," indicating its suitability for infant and pediatric populations, though it is also used in adult critical care. The "7%" refers to the concentration of amino acids in the solution.

The active components of AMINOSYN-PF 7% include essential and non-essential amino acids, typically balanced to mimic the composition of human protein. Specific amino acid profiles can vary slightly between manufacturers and formulations, but common components include L-Alanine, L-Arginine, L-Aspartic Acid, L-Cysteine Hydrochloride, L-Glutamic Acid, Glycine, L-Histidine, L-Isoleucine, L-Leucine, L-Lysine Hydrochloride, L-Methionine, L-Phenylalanine, L-Proline, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, and L-Valine. Electrolytes such as sodium, potassium, and acetate are also present to maintain fluid and electrolyte balance [1].

The drug's primary indication is the prevention and treatment of negative nitrogen balance in patients who are unable to consume adequate protein orally or enterally. This includes patients with severe burns, trauma, sepsis, gastrointestinal disorders, or those undergoing major surgery. Its use is particularly important in pediatric intensive care units (PICUs) where nutritional requirements are precise and metabolic demands are high.

Key Market Drivers

The market for parenteral amino acid solutions like AMINOSYN-PF 7% is shaped by several interconnected factors:

Growing Prevalence of Critical Illness

The incidence of critical illnesses requiring intensive care is a primary driver. Conditions such as sepsis, acute respiratory distress syndrome (ARDS), severe trauma, and complex surgical procedures often necessitate parenteral nutrition (PN). As global populations age and lifestyle-related diseases proliferate, the demand for critical care services, and by extension, PN solutions, is expected to rise.

• Sepsis: The World Health Organization (WHO) estimates that sepsis affects millions globally each year, with high mortality rates. Patients with sepsis experience increased metabolic demands and often have impaired gastrointestinal function, making PN essential [2].
• Trauma: Major trauma cases, including road traffic accidents and industrial injuries, lead to significant catabolic states requiring substantial nutritional support.
• Oncology: Cancer patients undergoing chemotherapy or radiation therapy, or those with malignancies affecting the gastrointestinal tract, frequently require PN to maintain nutritional status and support treatment tolerance.

Advancements in Medical Nutrition

Continuous innovation in medical nutrition is expanding the utility and efficacy of parenteral amino acid solutions. Research focuses on optimizing amino acid profiles to better meet the specific metabolic needs of different patient populations, such as neonates, pediatric patients, critically ill adults, and patients with specific organ dysfunction (e.g., liver or kidney disease).

• Tailored Formulations: Development of specialized amino acid mixtures with enhanced bioavailability and targeted delivery of specific amino acids (e.g., glutamine) can improve patient outcomes.
• Parenteral Nutrition Protocols: Evidence-based guidelines and protocols for the initiation and management of PN are becoming more refined, leading to more consistent and effective use of amino acid solutions [3].

Pediatric Nutrition Requirements

The "PF" designation highlights a significant segment: pediatric nutrition. Infants and children have unique and rapidly changing nutritional needs that are critical for growth and development. AMINOSYN-PF 7% is formulated to meet these specific requirements, addressing challenges in premature infants, neonates with congenital abnormalities, and children with chronic diseases.

• Premature Infants: Very low birth weight (VLBW) infants often have immature gastrointestinal systems and require PN for early nutritional delivery to support growth and prevent complications such as necrotizing enterocolitis.
• Congenital Disorders: Infants born with congenital heart defects, intestinal atresia, or other gastrointestinal anomalies may require long-term PN.

Increased Demand in Emerging Markets

As healthcare infrastructure improves and access to advanced medical treatments expands in emerging economies, the demand for sophisticated nutritional therapies, including parenteral amino acid solutions, is increasing. Government initiatives to improve public health and the growing presence of multinational pharmaceutical companies in these regions contribute to market growth.

Financial Trajectory and Market Valuation

The financial trajectory of AMINOSYN-PF 7% is subject to patent protection, generic competition, pricing strategies, and market penetration.

Patent Exclusivity and Generic Competition

The primary patent for the original formulation of AMINOSYN-PF 7% has likely expired. Pharmaceutical products, especially those with established formulations like amino acid solutions, often face generic competition once patent protection lapses.

• Original Manufacturer's Position: The originator company may have strategies to maintain market share, such as brand loyalty, superior product quality control, specialized distribution networks, or development of next-generation formulations.
• Generic Entry: The entry of generic versions of amino acid solutions can significantly reduce market prices and capture a substantial share of the market, driven by cost-effectiveness for healthcare providers and payers. This can lead to a decline in revenue for the original product if it cannot compete on price or differentiation.
• Exclusivity: The market value of a patented drug is typically high during its exclusivity period. Post-patent, the value shifts towards volume and market share in a more competitive landscape.

Pricing and Reimbursement

Pricing of AMINOSYN-PF 7% is influenced by manufacturing costs, research and development investment (for initial development and any subsequent formulation improvements), marketing, and the perceived clinical value. Reimbursement policies by government payers (e.g., Medicare, Medicaid) and private insurers play a crucial role in market access and affordability.

• Cost of Goods Sold (COGS): The cost of sourcing high-quality amino acids, sterile manufacturing processes, and packaging are significant components of COGS.
• Value-Based Pricing: In some markets, pricing may be influenced by the demonstrated clinical benefits and cost savings associated with reduced hospital stays or fewer complications when using the product.
• Reimbursement Rates: Fluctuations in reimbursement rates for parenteral nutrition can directly impact the profitability and market penetration of AMINOSYN-PF 7%.

Market Size and Growth Projections

The global parenteral nutrition market, which includes amino acid solutions, is projected to grow steadily. Reports from market research firms project a compound annual growth rate (CAGR) typically ranging from 5% to 8% over the next five to seven years.

• Global Market Value: The global parenteral nutrition market was valued at approximately USD 6.5 billion in 2022 and is forecast to reach over USD 10 billion by 2029 [4]. AMINOSYN-PF 7%, as a specific product within this category, contributes to this overall market valuation.
• Regional Growth: North America and Europe are currently the largest markets due to advanced healthcare infrastructure and high prevalence of critical care. However, Asia-Pacific is expected to witness the fastest growth due to increasing healthcare expenditure, rising chronic disease rates, and expanding access to advanced medical treatments.

Manufacturing and Supply Chain Considerations

The manufacturing of sterile parenteral solutions like AMINOSYN-PF 7% is complex and highly regulated, impacting cost and availability.

Regulatory Compliance

Manufacturing facilities must adhere to stringent Good Manufacturing Practices (GMP) mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes:

• Sterility Assurance: Rigorous validation of sterilization processes (e.g., terminal sterilization, aseptic processing) and environmental monitoring to prevent microbial contamination.
• Quality Control: Comprehensive testing of raw materials, in-process samples, and finished products to ensure purity, potency, and stability.
• Traceability: Robust systems for tracking raw materials and finished products throughout the supply chain.

Supply Chain Resilience

The supply chain for critical pharmaceutical products is vulnerable to disruptions. Factors affecting AMINOSYN-PF 7% include:

• Raw Material Sourcing: Dependence on a limited number of suppliers for high-purity amino acids can create single points of failure.
• Geopolitical Factors: Trade disputes, pandemics, or natural disasters can interrupt global supply routes.
• Manufacturing Capacity: Ensuring adequate manufacturing capacity to meet demand, especially during public health crises, is crucial.

Cost of Manufacturing

The cost of producing AMINOSYN-PF 7% is influenced by:

• Raw Material Purity and Cost: Pharmaceutical-grade amino acids are expensive.
• Sterile Manufacturing Infrastructure: Investment in and maintenance of sterile facilities are substantial.
• Quality Assurance and Control: Extensive testing and validation add to operational costs.
• Packaging: Specialized sterile packaging materials are required.

Competitive Landscape

The market for parenteral amino acid solutions is competitive, with several global players offering similar products. Competitors include:

• Baxter International Inc.: Offers a range of parenteral nutrition products, including amino acid solutions.
• Fresenius Kabi AG: A significant player in the IV drug manufacturing space, with its own portfolio of amino acid solutions.
• B. Braun Melsungen AG: Provides a comprehensive range of infusion therapies, including parenteral nutrition.
• Other Generic Manufacturers: Numerous regional and global pharmaceutical companies manufacture generic amino acid solutions, often at lower price points.

The differentiation between products can lie in the specific amino acid profiles, the presence of additional components (e.g., electrolytes, trace elements), packaging innovations, and established brand reputation and trust among healthcare providers.

Key Takeaways

• AMINOSYN-PF 7% is a vital parenteral amino acid solution for patients requiring intravenous nutritional support, particularly in critical care and pediatric settings.
• Market growth is driven by the increasing prevalence of critical illnesses, advancements in medical nutrition, and specific demands in pediatric care.
• The financial trajectory is impacted by patent expiration and subsequent generic competition, pricing pressures, and reimbursement policies.
• Manufacturing is complex, requiring strict regulatory compliance and a resilient supply chain, which contributes to product cost.
• The competitive landscape includes major pharmaceutical companies and numerous generic manufacturers, emphasizing price and product differentiation as key market factors.

FAQs

What are the primary indications for AMINOSYN-PF 7%?

The primary indications for AMINOSYN-PF 7% include the prevention and treatment of negative nitrogen balance in patients who are unable to consume adequate protein orally or enterally. This encompasses patients with severe burns, trauma, sepsis, gastrointestinal disorders, and those undergoing major surgery. It is also specifically formulated for pediatric patients requiring intravenous nutritional support.

How does patent expiration affect the market for AMINOSYN-PF 7%?

Patent expiration generally leads to the introduction of generic versions of the drug. This increases market competition, often resulting in lower prices and a potential decrease in revenue for the originator product if it cannot compete on cost or differentiation. Market share may shift towards generic manufacturers who can offer more cost-effective alternatives.

What are the key challenges in manufacturing AMINOSYN-PF 7%?

Key manufacturing challenges include maintaining stringent Good Manufacturing Practices (GMP) to ensure sterility and product purity, managing a complex global supply chain for high-quality raw materials, and the high cost associated with sterile production environments and rigorous quality control processes.

How does the growth in emerging markets impact the demand for AMINOSYN-PF 7%?

The growth in emerging markets, characterized by improving healthcare infrastructure, increasing healthcare expenditure, and a rising incidence of chronic diseases, is expected to drive significant demand for advanced medical treatments like parenteral nutrition. This expansion offers opportunities for increased market penetration for products like AMINOSYN-PF 7%.

What differentiates AMINOSYN-PF 7% from other parenteral amino acid solutions?

Differentiation can stem from specific amino acid profiles designed for optimal patient response, the inclusion of essential electrolytes or trace elements, unique packaging solutions for improved usability or stability, and the established reputation and clinical trust built by the manufacturing company. The "PF" designation specifically highlights its pediatric formulation.

Citations

[1] Micromedex Solutions. (2023). AMINOSYN® PF 7%. Truven Health Analytics. [2] Rudd, K. E., Johnson, S. C., Agesa, K. M., Al-Lawati, M. N., Arnold, S. R., Creanga, A. A., & Simon, K. J. (2020). Global, regional, and national sepsis incidence and mortality, 1990–2017: An analysis for the Global Burden of Disease Study. The Lancet, 395(10219), 200-211. [3] McCray, S., & Pironi, G. (2021). Parenteral nutrition: An overview. Clinical Nutrition ESPEN, 44, 3-10. [4] Grand View Research. (2023). Parenteral Nutrition Market Size, Share & Trends Analysis Report By Product (Amino Acids, Carbohydrates, Fats, Vitamins & Minerals), By Type (Customized, Ready-to-Use), By Application (Oncology, Gastroenterology, Neonatology, Parenteral Nutrition Deficiency), By End-use (Hospital, Homecare, Clinics), By Region, And Segment Forecasts, 2023 - 2030.